# US 2023/0054593 A1 · Methods of treating fragile x syndrome with reelin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054593 A1
- Document ID: US20230054593A1
- Status: Published application
- Kind: A1
- Application number: 17/793,506
- Filed: 2021-01-19
- Published: 2023-02-23
- Earliest claimed: 2020-01-17
- Assignees: University of South Florida
- Applicants: University of South Florida
- Inventors: Edwin WEEBER; Kevin R. NASH; Qingyou LI; Nicole MORRILL
- Web page: https://patentgrep.com/patent/US20230054593A1

## CPC

- A61K 38/482: {Serine endopeptidases (3.4.21)}
- C12N 15/86: Viral vectors
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0306: Animal model for genetic diseases
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/41: containing a Myc-tag
- C07K 2319/61: containing an enzyme fusion for detection (lacZ, luciferase)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Fragile X syndrome (FXS) is the most common inherited form of human intellectual disability. FXS is caused by loss of function of the FMR1 gene which results in significant behavioral deficits in spatial learning and memory tests. FMR1−/− knockout mice share many of the learning deficits and decreased synaptic function encountered in FXS patients. Anecdotal evidence indicates a reduction in the amount of Reelin, a large extracellular signaling protein important for normal hippocampal synaptic plasticity, may play role in the etiology of FXS. Disclosed herein is a rAAV9 Reelin viral vector expressing a REELIN repeat R3+R6 fusion protein that is shown to rescue cognitive deficits in FMR1−/− mice as evaluated in the Hidden Platform Water Maze, Open Field and Fear Conditioning. Reelin gene therapy is therefore potentially a novel therapeutic for the treatment of Fragile X Syndrome.

## Claims

### Claim 1

A method of treating at least one symptom of a patient suffering from Fragile X Syndrome, comprising administering a therapeutically effective amount of a REELIN adeno-associated viral (AAV) vector expressing a secreted recombinant REELIN fusion protein, wherein the REELIN fusion protein comprises an N-terminal REELIN R3 repeat encoded by the nucleotide sequence of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the recombinant REELIN fusion protein does not comprise a REELIN repeat R4 and R5.

### Claim 3 (depends on 1)

The method of claim 1, wherein the recombinant REELIN fusion protein further comprises a C-terminal REELIN R6 repeat encoded by the nucleotide sequence of SEQ ID NO: 5.

### Claim 4 (depends on 1)

The method of claim 1, wherein the recombinant REELIN fusion protein has the amino acid sequence of SEQ ID NO: 10.

### Claim 5 (depends on 4)

The method of claim 4, wherein the REELIN adeno-associated viral (AAV) vector further comprises an IgKappa signal sequence fused in frame to the N-terminal REELIN R3 repeat.

### Claim 6 (depends on 4)

The method of claim 4, wherein the REELIN adeno-associated viral (AAV) vector is administered intraarterially, intravenously, intracerebrally, intraventricularly or intrathecally.

### Claim 7 (depends on 4)

The method of claim 4, wherein the REELIN adeno-associated viral (AAV) vector is administered by bilateral intracerebral injection.

### Claim 8 (depends on 4)

The method of claim 4, wherein REELIN adeno-associated viral (AAV) vector is administered by intracerebroventricular (ICV) injection.

### Claim 9 (depends on 8)

The method of claim 8, wherein the REELIN AAV vector is effective at mitigating at least one cognitive defect caused by Fragile X Syndrome.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mitigation of the at least one cognitive defect caused by Fragile X Syndrome is equivalent to the mitigation of the cognitive defect obtained after intracerebroventricular (ICV) injection of a R3456 REELIN repeat protein.

### Claim 11 (depends on 9)

The method of claim 9, wherein the at least one cognitive defect of Fragile X Syndrome comprises hyperactivity.

### Claim 12 (depends on 9)

The method of claim 9, wherein the at least one cognitive defect of Fragile X Syndrome comprises associative learning.

### Claim 13 (depends on 9)

The method of claim 9, wherein the at least one cognitive defect of Fragile X Syndrome comprises spatial learning and memory.

### Claim 14 (depends on 1)

The method of claim 1, wherein the symptom of Fragile X Syndrome is selected from the group consisting of a deficiency in dendritic spine density, diminished long-term potentiation, diminished synaptic plasticity and associative learning deficits.

### Claim 15 (depends on 1)

The method of claim 1, wherein the recombinant REELIN fusion protein induces dimerization of an ApoER2 receptor.

### Claim 16 (depends on 1)

The method of claim 1, wherein the recombinant REELIN fusion protein activates the phosphorylation of DAB1 and ERK1/2.

### Claim 17

A method of treating at least one symptom of a patient suffering from Fragile X Syndrome, comprising administering a therapeutically effective amount of a REELIN adeno-associated viral (AAV) vector expressing a secreted recombinant REELIN fusion protein, wherein the fusion protein comprises an C-terminal R6 REELIN repeat encoded by the nucleotide sequence of SEQ ID NO: 5.

### Claim 18

A method of treating at least one symptom of a patient suffering from Fragile X Syndrome, comprising administering a therapeutically effective amount of a REELIN adeno-associated viral (AAV) vector expressing a secreted recombinant REELIN fusion protein, wherein the REELIN fusion protein does not comprise REELIN repeats R4 or R5.
